drugset / Trial / NCT02183610

Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers

NCT02183610

Phase 1 Completed 12 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To determine the basic pharmacokinetics of BI 1356 BS, its metabolite CD 1750 XX and radioactivity including excretion mass balance, excretion pathways and metabolism following the intravenous and oral administration of \[14C\] BI 1356 BS

Timeline

Start
2006-07
Primary completion
2006-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule 5 mg Oral
Subject Linagliptin Small molecule 10 mg Oral

Indications

No indication recorded.